Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists | Zendy

Deborah Siegal | Zendy; Jovana Yudin | Zendy; Scott Kaatz | Zendy; James D. Douketis | Zendy; Wendy Lim | Zendy; Alex C. Spyropoulos | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Periprocedural Heparin Bridging in Patients Receiving Vitamin K Antagonists

Author(s) -

Deborah Siegal,

Jovana Yudin,

Scott Kaatz,

James D. Douketis,

Wendy Lim,

Alex C. Spyropoulos

Publication year - 2012

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.105221

Subject(s) - medicine , odds ratio , vitamin k antagonist , confidence interval , low molecular weight heparin , heparin , randomized controlled trial , incidence (geometry) , lower risk , gastroenterology , warfarin , physics , optics , atrial fibrillation

Periprocedural bridging with unfractionated heparin or low-molecular-weight heparin aims to reduce the risk of thromboembolic events in patients receiving long-term vitamin K antagonists. Optimal periprocedural anticoagulation has not been established.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research